A Phase 3 interventional study of Placebo and Sovateltide in Traumatic Brain Injury, sponsored by Pharmazz, Inc.. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Pharmazz, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Traumatic brain injury (TBI) remains a leading cause of global disability, yet current clinical management is limited to supportive care and pressure stabilization using hyperosmolar therapies like mannitol and hypertonic saline. These strategies fail to address the destructive cellular cascades that persist long after the initial impact, leaving 66.3% of severe TBI patients with permanent cognitive and neurological deficits. To bridge this critical unmet medical need, the therapeutic focus must shift toward neuroprotective and neuroregenerative agents that actively block secondary injury cascades such as excitotoxicity, apoptosis, and chronic neuroinflammation.
Sovateltide is a selective endothelin-B receptor agonist. It was previously reported to reduce apoptosis, stimulate neurogenesis, and improve functional recovery. Unlike most TBI candidates restricted to preclinical phases, sovateltide possesses a robust human safety and tolerability profile established across Phase I, II, III, and IV ischemic stroke trials.
We conducted a preclinical study in Wistar rats with induced TBI and showed that sovateltide effectively preserved BBB integrity, a critical determinant of post-injury outcomes, and significantly reduced neuronal apoptosis, as evidenced by decreased expression of caspase-3 and caspase-6, key markers of programmed cell death. Treated animals also exhibited notable improvements in neurobehavioral performance, reflecting functional recovery likely attributable to the drug's antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. These results align with earlier evidence showing that ETB receptor activation enhances angiogenesis, neurogenesis, and synaptic remodeling, processes essential for neural repair following brain injury.
The present study has been designed to advance sovateltide (IRL-1620) into a pivotal Phase III clinical trial for acute traumatic brain injury (TBI). With millions affected annually and zero approved neuroprotective pharmacotherapies available, this milestone marks a critical step forward in addressing one of modern medicine's greatest unmet needs. By harnessing our proprietary neural repair discovery platform, sovateltide targets the cascade of secondary cell death while stimulating neurogenesis and angiogenesis. Building on the strong momentum of our ongoing global Phase III RESPECT-ETB study in acute ischemic stroke, this study will further validate the broad therapeutic potential of our endothelin-B receptor platform across severe acute neurovascular conditions.
A traumatic brain injury (TBI) is a form of brain damage that results from an external mechanical force impacting the head or body, such as a sudden blow, jolt, or wound. The injuries could be penetrating (open) ones - commonly seen in motor vehicle accidents, falls, sports injuries, and explosive blasts in which an object such as a bullet, shrapnel, or bone fragment breaches the skull and directly damages brain tissue, or non-penetrating (closed or blunt) ones, which result from rapid acceleration, deceleration, or rotational forces that cause the brain to move within the skull. Based on the timing of the impact and damage, these injuries are categorized as primary or secondary. Primary injuries, such as contusions, lacerations, or hemorrhage, occur at the moment of impact and involve immediate damage. Secondary injury develops over time through complex biochemical and physiological processes such as increased intracranial pressure, cerebral edema, ischemia, excitotoxicity, oxidative stress, and neuroinflammation, which can worsen neurological outcomes later.
According to the Global Burden of Diseases database in 2021, there were 20.84 million incident cases and 37.93 million prevalent cases of TBI worldwide. Between 1990 and 2021, the global number of TBI incidents and prevalent cases increased by 22.6% and 53.3%, respectively; however, the age-standardized incidence rate declined by 0.11%. These rates generally increased with age and were higher in males than in females. The highest age-standardized prevalence and years lived with disability rates were observed in Eastern and Central Europe. Globally, falls were the leading cause of TBI in 2021, followed by road injuries, violence, and exposure to mechanical forces.
Currently, no therapeutic agent is approved for TBI because of the injury's biological complexity, heterogeneity in patient presentation, and limited translation of preclinical success into human trials. Hence, future progress likely depends on developing drugs or combination therapies with multimodal mechanisms of action that support neural cell protection, regeneration, repair, and functional restoration. Moreover, TBI pathophysiology is complex, involving vascular damage, inflammation, apoptosis, and other processes that trigger neuronal damage and death. A thorough understanding of TBI pathophysiology is essential for developing novel therapeutic agents that provide neuroprotection by curbing inflammation, enhancing angiogenesis, reducing hypoxic episodes, excitotoxicity, and apoptosis, and promoting neuroregeneration in injured brain tissue. Endothelin signaling regulates these pathophysiological events in the mammalian neurovascular system; therefore, the endothelin system could be a potent drug-development target in TBI.
Sovateltide (TycamzziTM, IRL-1620, PMZ-1620) is a first-in-class ETB receptor agonist approved in India for treating acute ischemic stroke (AIS), promoting neuroprotection and regeneration via neuron and blood vessel growth. We evaluated the neuroprotective potential of sovateltide in the Marmarou weight-drop rat model of traumatic brain injury (TBI). TBI onset in rats damaged blood-brain barrier (BBB) and increased brain water content, inflammation and oxidative stress. Neuronal damage in the prefrontal cortex and hippocampal subfields (CA1-CA3 and dentate gyrus) was seen on day 1 post-injury. A marked increase in Neurobehavioral Severity Score-Revised (NSS-R), indicating neurological impairment, was also observed. Rats were either treated with sovateltide (5μg/kg) or mannitol (20% w/v) or Normal Saline (5ml/kg) administered three times a day on 1st, 3rd and 6th day after induction of TBI. Animals treated with sovateltide or mannitol showed progressive functional recovery with a significantly reduced NSS-R score compared to untreated TBI rats by day 7. These animals also showed a clear trend toward behavioral improvement; however, anxiety levels and locomotor activity remained comparable. Damage to the BBB, reflected by elevated Evans Blue Dye elution, was substantially reduced in sovateltide-treated rats. Sovateltide exhibited antioxidant activities and reduced malondialdehyde (MDA) levels, restoring superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) levels to near-normal. Sovateltide-treated rats had decreased inflammatory indicators/mediators (e.g., NF-κB, IL-6, and TNF-α) compared with untreated and mannitol-treated animals. At the tissue level, sovateltide-treated animals had better-preserved neural tissue architecture, like sham animals, than control and mannitol-treated animals. Apoptotic markers caspase-3 and caspase-6 were significantly reduced in sovateltide animals, along with attenuation of astrocytic activation indicated by decreased GFAP in cortical and hippocampal regions. Thus, sovateltide confers multimodal neuroprotection by alleviating oxidative stress, suppressing neuroinflammation, preserving BBB integrity and neuronal morphology, and inhibiting apoptosis following TBI.
A TBI study in Wistar rats found that sovateltide preserved BBB integrity and reduced apoptosis, as evidenced by decreased caspase-3 and caspase-6 expression and improved neurobehavioral outcomes, likely due to its antioxidant and anti-apoptotic properties. Overall, studies show that the endothelin system, particularly ETB receptor signaling, represents a promising therapeutic axis that can address TBI heterogeneity by integrating vascular protection, anti-inflammatory effects, and neural regeneration. Unlike traditional monotherapies that target isolated pathways, ETB activation through sovateltide would offer a multimodal approach to target the full spectrum of TBI, from acute neuroprotection to long-term neural repair.
The pathophysiological similarities between stroke and TBI-specifically the roles of ischemia, inflammation, and the need for remodeling-provide a strong "proof of concept" for the application of sovateltide in TBI.
1,722 studies on the registry are indexed under Brain Injuries, Traumatic; 448 are open to participants now.
This study's planned enrollment of 214 is above the median of 52 across 1,089 interventional studies indexed under Brain Injuries, Traumatic.
Browse Brain Injuries, Traumatic studies →Pharmazz, Inc. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A participant will be eligible for inclusion in the study if the participant fulfills the following criteria:
Exclusion Criteria:
A participant will not be considered eligible for inclusion in this study if the participant meets any of the following exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Sovateltide
The reference product is a matching placebo for sovateltide. It is a sterile lyophilized injection consisting of excipients formulated without the active ingredient in a 5.0 mL vial, to be reconstituted in 5 mL of normal saline (0.9% Sodium Chloride Injection).
The test product is sovateltide. It is available as a lyophilized injection containing 30 μg of sovateltide in a 5.0 mL vial, to be reconstituted in 5 mL normal saline (0.9% Sodium Chloride Injection).
Also known as: IRL-1620
Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 90 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.
Score Range: 1 to 8 (minimum: 1, maximum: 8); Direction of Score: Higher scores represent a better outcome (1 indicates Death; 7 indicates Lower Good Recovery; 8 indicates Upper Good Recovery).
Time frame: 90 days
Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 180 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.
Score Range: 1 to 8 (minimum: 1, maximum: 8); Direction of Score: Higher scores represent a better outcome (1 indicates Death; 7 indicates Lower Good Recovery; 8 indicates Upper Good Recovery).
Time frame: 180 days
Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 30 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.
Score Range: 1 to 8 (minimum: 1, maximum: 8); Direction of Score: Higher scores represent a better outcome (1 indicates Death; 7 indicates Lower Good Recovery; 8 indicates Upper Good Recovery).
Time frame: 30 days
Proportion of patients with an improvement in Disability Rating Scale (DRS) to less than or equal to 3 at Days 30, 90, and 180 post randomization. Score range: 0 to 30; higher scores represent a worse outcome.
Score Range: 0 to 30 (minimum: 0, maximum: 30); Direction of Score: Higher scores represent a worse outcome (0 indicates no disability; 30 indicates death).
Time frame: 180 days
Change in the Montreal Cognitive Assessment (MoCA) at Days 30, 90, and 180 post-randomization. Score range: 0 to 30; higher scores represent a better outcome.
Score Range: 0 to 30 (minimum: 0, maximum: 30); Direction of Score: Higher scores represent a better outcome (scores of 26 and above are generally considered normal cognitive function; lower scores indicate greater cognitive impairment).
Time frame: 180 days
Change in the quality-of-life outcomes using Short Form (36) Health Survey (SF-36) at Days 30, 60, 90, 135, and 180 post-randomization.
Time frame: 180 days
Hospital free days from randomization to Day 90.
Time frame: 90 days
ICU free days from randomization to Day 90.
Time frame: 90 days
Incidence of all-cause mortality from randomization to Day 180.
Time frame: 180 days
Proportion of patients with adverse events (AEs) and serious adverse events (SAEs).
Time frame: 180 days
No study locations are listed for this record.
Plan to share: Yes
Supporting information: Study protocol
Start is estimated for Dec 2026; primary completion for Feb 2028, 14 months later.
Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sovateltide
Pharmazz, Inc.